We are focused on the treatment of hemophilia using our high potency coagulation proteases that promote blood clotting. We plan to initiate two clinical trials in 2017, one in patients with hemophilia B and the other in hemophilia inhibitor patients.
Next Generation Hemostasis Programs
*(formerly known as CB 813d)
|Anti-C3: CB 2782||Renal DGF, IRI cardiovascular|
|Anti-C3: Ophthalmic||Dry AMD|